Eylea HD market seen expanding on demand for longer-acting eye treatments
The Business Research Company says the global Eylea HD market is set for continued growth through 2035 as retinal disease cases rise and demand builds for longer-acting anti-VEGF therapies. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.
Why it matters: - Demand is rising for eye treatments that reduce injection frequency while keeping efficacy high. - Eylea HD fits that shift because it is a higher-dose aflibercept therapy for retinal disease. - The market outlook points to broader growth in ophthalmology as diabetes, aging and retinal disorders expand the patient pool.
What happened: - The Business Research Company published its Eylea HD Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 4, 2026. - The report says the Eylea HD market is undergoing significant change as treatment advances and patient needs evolve. - The analysis covers market size, trends, growth drivers, regional performance and the role of personalized medicine. - A free sample report is available here. - The full report is available here.
The details: - Eylea HD is a high-dose version of aflibercept, a vascular endothelial growth factor inhibitor used for retinal conditions. - The drug is delivered through intravitreal injection and contains 8 mg of active ingredient, compared with 2 mg in standard Eylea. - The higher dose is designed to extend time between treatments while maintaining safety and effectiveness comparable to the original formulation. - The report links past market growth to high retinal disease rates, frequent dosing needs for earlier therapies, proven anti-VEGF effectiveness, an aging population and the expansion of ophthalmology clinics. - Future growth is expected to come from rising diabetic retinopathy cases, demand for long-acting formulations, better ocular drug delivery systems, more elderly patients and more outpatient eye care centers. - The report highlights a shift toward longer dosing intervals, stronger demand for potent anti-VEGF treatments, lower injection frequency, better retinal disease management and improved adherence. - The report says growing eye disorder prevalence is a major demand driver. - Conditions cited include refractive errors, cataracts, glaucoma, macular degeneration, diabetic retinopathy and other retinal diseases. - The report points to aging populations, more screen time, environmental factors, genetic susceptibility and chronic disease as contributors to higher eye-disease rates. - In May 2024, the US Centers for Disease Control and Prevention reported that 17.2% of Americans age 40 and older, or about 20.5 million people, had cataracts in at least one eye. - The CDC projected that cataract cases in that group will exceed 30 million by 2028. - The report says Eylea HD targets abnormal retinal blood vessel growth and fluid leakage. - Personalized medicine is also shaping demand by tailoring treatment to genetic, environmental and lifestyle profiles. - The report says personalized medicine is supported by genomics, better diagnostics, improved outcomes, fewer side effects, patient demand, regulatory support and long-term cost efficiency. - The Personalized Medicine Coalition said in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - In 2025, North America held the largest share of the Eylea HD market. - The report says Asia-Pacific is expected to be the fastest-growing region over the next several years. - The regional analysis also includes Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables.
Between the lines: - The report frames Eylea HD as part of a broader shift in ophthalmology toward fewer injections and more durable therapies. - Personalized medicine appears to be strengthening the case for targeted retinal treatments, especially as precision diagnostics improve. - North America’s lead suggests the market is currently strongest where care access and disease detection are more advanced, while Asia-Pacific’s forecast growth points to widening global adoption.
What's next: - The market is expected to keep expanding through 2035 as retinal disease prevalence rises and outpatient eye care access improves. - More patients may move toward longer-interval anti-VEGF treatment regimens if clinical and commercial adoption continues. - The company is offering expert contact channels for more information and follow-up discussions.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Healthcare Press Releases
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.